NCT06354231 is a Phase 2 clinical trial of DV in Renal Insufficiency, sponsored by Fudan University.

Who is sponsoring NCT06354231?

NCT06354231 is sponsored by Fudan University.

What drugs are being tested in NCT06354231?

Interventions in NCT06354231: DV, Toripalimab, Laser surgery.

What condition does NCT06354231 study?

NCT06354231 studies Renal Insufficiency, Upper Urinary Tract Urothelial Carcinoma, Solitary Kidney.

Is NCT06354231 still recruiting?

NCT06354231 is currently recruiting now. Last updated 11 April 2024.

Last reviewed 2024-04-11 · How we verify

NCT06354231

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC

Recruiting now Phase 2 Last updated 11 April 2024

What this trial tests

Phase 2 trial testing DV in Renal Insufficiency in 20 participants. Currently enrolling.

Timeline

20 July 2023

Primary endpoint
30 December 2026

30 December 2026

Quick facts

Lead sponsor	Fudan University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	20 July 2023
Primary completion	30 December 2026
Estimated completion	30 December 2026
Sites	1 location across China

Drugs / interventions tested

DV — full drug profile →
Toripalimab (TORIPALIMAB) — full drug profile →
Laser surgery

Conditions studied

Renal Insufficiency — all drugs for Renal Insufficiency →
Upper Urinary Tract Urothelial Carcinoma — all drugs for Upper Urinary Tract Urothelial Carcinoma →
Solitary Kidney — all drugs for Solitary Kidney →

Sponsor

Fudan University

Who can join

18 and older, any sex, with Renal Insufficiency or Upper Urinary Tract Urothelial Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Approximately 20 participants will be enrolled in the study to evaluate the efficacy and safety of the combination of DV (DV, 2.0 mg/kg, intravenously administered every 2 weeks) and toripalimab (toripalimab, 3.0mg/kg, intravenously administered every 2 weeks). Subjects will receive 6 cycles of DV and toripalimab, followed by laser surgery to remove ureteral or renal pelvis tumors, followed by 12 cycles of DV and 1 year of toripalimab consolidation therapy. Efficacy and safety were evaluated by cystoscopy, ureteroscopy, laboratory tests, and imaging examinations after treatment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Urothelial carcinoma of the bladder presenting with abnormal inguinal metastasis.
Wang H, Hua S. · · 2025 · PMID 40027079 · DOI 10.1016/j.eucr.2025.102983

Verify or expand the search:

Other recruiting trials for Renal Insufficiency

Currently open trials in the same condition.

NCT06890208 — Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave · recruiting
NCT07001436 — A Pharmacokinetics and Safety Study of Azvudine Tablets in Subjects With Mild-To-Moderate GFR Decline in Renal Insuffici · Phase 1 · recruiting
NCT06431789 — Prospective Observational Association Between SLCO1B1 Gene Polymorphism and the Anti-factor Xa Activity of Edoxaban in P · recruiting
NCT05428631 — Tolerability and Safety of CARDIOMEMS™ Intracardiac Continuous Cardiac Hemodynamic Monitoring Device in Patients with Ca · NA · recruiting
NCT05242315 — Extended-Release Tacrolimus Following Liver Transplantation · Phase 4 · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06354231 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 11 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06354231.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing